Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/926
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSOUZA, Paola da Costa-
dc.contributor.authorPARRA, Edwin Roger-
dc.contributor.authorATANAZIO, Marcelo Junqueira-
dc.contributor.authorSILVA, Osmar Bianchi da-
dc.contributor.authorNOLETO, Gustavo Sousa-
dc.contributor.authorAB'SABER, Alexandre Muxfeldt-
dc.contributor.authorFERNEZLIAN, Sandra de Morais-
dc.contributor.authorTAKAGAKI, Tereza-
dc.contributor.authorCAPELOZZI, Vera Luiza-
dc.date.accessioned2013-07-30T15:14:51Z-
dc.date.available2013-07-30T15:14:51Z-
dc.date.issued2012-
dc.identifier.citationHISTOPATHOLOGY, v.61, n.4, p.587-596, 2012-
dc.identifier.issn0309-0167-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/926-
dc.description.abstractAims: Development of effective immune-based therapies for patients with non-small-cell lung carcinoma (NSCLC) depends on an accurate characterization of complex interactions that occur between immune cells and the tumour environment. Methods and results: Innate and adaptive immune responses were evaluated in relation to prognosis in 65 patients with surgically excised NSCLC. Immunohistochemistry and morphometry were used to determine the abundance and distribution of immune cells. We found low numbers of immune cells and levels of cytokines in the tumour environment when compared with surrounding parenchyma. Smoking was associated inversely with the adaptive immune response and directly with innate immunity. We observed a prominent adaptive immune response in squamous cell carcinomas (SCC) but greater innate immune responses in adenocarcinomas and large cell carcinomas. Cox model analysis showed a low risk of death for smoking <41 packs/year, N-0 tambour stage, squamous carcinoma, CD4(+) > 16.81% and macrophages/monocytes >4.5%. Collectively, the data indicate that in NSCLC there is not a substantive local immune cell infiltrate within the tumour. Conclusion: Although immune cell infiltration is limited in NSCLC it appears to have an impact on prognosis and this may be of relevance for new immunotherapeutic approaches.-
dc.description.sponsorshipNational Council for Scientific and Technological Development (CNPq)-
dc.description.sponsorshipFoundation for the Support of Research of the State of Sao Paulo [FAPESP 07/56247-3, 07/58494-8]-
dc.description.sponsorshipLaboratories for Medical Research, Hospital das Clinicas, University of Sao Paulo Medical School [FMUSP-HC/LIMs]-
dc.language.isoeng-
dc.publisherWILEY-BLACKWELL-
dc.relation.ispartofHistopathology-
dc.rightsrestrictedAccess-
dc.subjectcytokines-
dc.subjectimmune cells-
dc.subjectinterleukins-
dc.subjectlung cancer-
dc.subject.othernatural-killer-cells-
dc.subject.othernucleolar organizer region-
dc.subject.otherimmature dendritic cells-
dc.subject.othertumor-necrosis-factor-
dc.subject.otherprognostic value-
dc.subject.othermorphometric evaluation-
dc.subject.othert-lymphocytes-
dc.subject.otherlymph-nodes-
dc.subject.othercancer-
dc.subject.othersurvival-
dc.titleDifferent morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma-
dc.typearticle-
dc.rights.holderCopyright WILEY-BLACKWELL-
dc.identifier.doi10.1111/j.1365-2559.2012.04318.x-
dc.identifier.pmid22716510-
dc.subject.wosCell Biology-
dc.subject.wosPathology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalATANAZIO, Marcelo Junqueira:Univ Sao Paulo, Dept Patol, Fac Med, BR-01296903 Sao Paulo, Brazil-
hcfmusp.description.beginpage587-
hcfmusp.description.endpage596-
hcfmusp.description.issue4-
hcfmusp.description.volume61-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84871919242-
hcfmusp.origem.idWOS:000310481800006-
hcfmusp.publisher.cityHOBOKEN-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAloysius MM, 2006, SURG-J R COLL SURG E, V4, P195-
hcfmusp.relation.referenceAl-Shibli K, 2009, HISTOPATHOLOGY, V55, P301, DOI 10.1111/j.1365-2559.2009.03379.x-
hcfmusp.relation.referenceAntonangelo L, 1997, CHEST, V111, P110, DOI 10.1378/chest.111.1.110-
hcfmusp.relation.referenceArenberg DA, 2000, CANCER IMMUNOL IMMUN, V49, P63, DOI 10.1007/s002620050603-
hcfmusp.relation.referenceBaleeiro RB, 2008, CANCER IMMUNOL IMMUN, V57, P1335, DOI 10.1007/s00262-008-0468-7-
hcfmusp.relation.referenceBanchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588-
hcfmusp.relation.referenceBARBUTO JAM, 1995, CANCER IMMUNOL IMMUN, V40, P31, DOI 10.1007/BF01517233-
hcfmusp.relation.referenceBell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417-
hcfmusp.relation.referenceBERNARDI FD, 1995, CHEST, V107, P614-
hcfmusp.relation.referenceBernardi FD, 1997, MODERN PATHOL, V10, P992-
hcfmusp.relation.referenceBingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027-
hcfmusp.relation.referenceBrambilla E, 2004, PATHOLOGY GENETICS T-
hcfmusp.relation.referenceCarvalho HA, 1997, HISTOPATHOLOGY, V31, P420, DOI 10.1046/j.1365-2559.1997.2940885.x-
hcfmusp.relation.referenceChan CW, 2008, CELL DEATH DIFFER, V15, P58, DOI 10.1038/sj.cdd.4402235-
hcfmusp.relation.referenceChan CW, 2006, NAT MED, V12, P207, DOI 10.1038/nm1352-
hcfmusp.relation.referenceChaux P, 1996, LAB INVEST, V74, P975-
hcfmusp.relation.referenceCoca S, 1997, CANCER, V79, P2320, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P-
hcfmusp.relation.referenceCoventry BJ, 2003, BRIT J CANCER, V89, P533, DOI 10.1038/sj.bjc.6601114-
hcfmusp.relation.referencede Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782-
hcfmusp.relation.referenceDimitriadou V, 1997, ANTICANCER RES, V17, P1541-
hcfmusp.relation.referenceDOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135-
hcfmusp.relation.referenceFricke I, 2006, IMMUNOL INVEST, V35, P459, DOI 10.1080/08820130600803429-
hcfmusp.relation.referenceGong Xuanju, 2000, Zhonghua Zhongliu Zazhi, V22, P135-
hcfmusp.relation.referenceGordon SB, 2002, BRIT MED BULL, V61, P45, DOI 10.1093/bmb/61.1.45-
hcfmusp.relation.referenceGreen RM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006860-
hcfmusp.relation.referenceIshigami S, 2000, CANCER, V88, P577, DOI 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V-
hcfmusp.relation.referenceIwamoto M, 2003, INT J CANCER, V104, P92, DOI 10.1002/ijc.10915-
hcfmusp.relation.referenceKataki A, 2002, J LAB CLIN MED, V140, P320, DOI 10.1067/mlc.2002.128317-
hcfmusp.relation.referenceMatheus RS, 2004, PATHOL RES PRACT, V200, P13, DOI 10.1016/j.prp.2003.12.007-
hcfmusp.relation.referenceMETA M, 1995, CANCER IMMUNOL IMMUN, V40, P235, DOI 10.1007/BF01519897-
hcfmusp.relation.referenceMinamoto H, 2003, HISTOPATHOLOGY, V43, P427, DOI 10.1046/j.1365-2559.2003.01704.x-
hcfmusp.relation.referenceMoriya K, 2010, CANCER IMMUNOL IMMUN, V59, P1083, DOI 10.1007/s00262-010-0835-z-
hcfmusp.relation.referenceNeves AR, 2005, CANCER IMMUNOL IMMUN, V54, P61, DOI 10.1007/s00262-004-0550-8-
hcfmusp.relation.referenceO'Mahony D, 2005, J CLIN ONCOL, V23, P1-
hcfmusp.relation.referenceParra ER, 2008, HISTOL HISTOPATHOL, V23, P987-
hcfmusp.relation.referencePorta C, 2007, ANTICANCER RES, V27, P165-
hcfmusp.relation.referenceRodrigues OR, 1997, JPN J CLIN ONCOL, V27, P298, DOI 10.1093/jjco/27.5.298-
hcfmusp.relation.referenceSaito DMS, 2007, HISTOPATHOLOGY, V50, P525, DOI 10.1111/j.1365-2559.2007.02623.x-
hcfmusp.relation.referenceSallusto P, 1994, J EXP MED, V179, P1109-
hcfmusp.relation.referenceSandel MH, 2005, CLIN CANCER RES, V11, P2576, DOI 10.1158/1078-0432.CCR-04-1448-
hcfmusp.relation.referenceSchrump D, 2005, CANC PRINCIPLES PRAC, P753-
hcfmusp.relation.referenceSouza P, 2010, HUM PATHOL, V41, P239, DOI 10.1016/j.humpath.2009.07.018-
hcfmusp.relation.referenceTAKAHASHI H, 1993, INT IMMUNOL, V5, P849, DOI 10.1093/intimm/5.8.849-
hcfmusp.relation.referenceTakanami I, 2001, J THORAC CARDIOV SUR, V121, P1058, DOI 10.1067/2001.113026-
hcfmusp.relation.referenceTataroglu C, 2004, LUNG CANCER-J IASLC, V43, P47, DOI 10.1016/j.lungcan.2003.08.013-
hcfmusp.relation.referenceVermaelen KY, 2001, J EXP MED, V193, P51-
hcfmusp.relation.referenceVillegas FR, 2002, LUNG CANCER-J IASLC, V35, P23, DOI 10.1016/S0169-5002(01)00292-6-
hcfmusp.relation.referenceWeibel ER, 1990, MODELS LUNG DIS MICR, P199-
hcfmusp.relation.referenceWelsh TJ, 2005, J CLIN ONCOL, V23, P8959, DOI 10.1200/JCO.2005.01.4910-
hcfmusp.relation.referenceWu J, 2003, ADV CANCER RES, V90, P127, DOI 10.1016/S0065-230X(03)90004-2-
hcfmusp.relation.referenceZHOU LJ, 1992, J IMMUNOL, V149, P735-
hcfmusp.relation.referenceZou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipCNPq-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.remissive.sponsorshipFMUSP-HC-
hcfmusp.citation.scopus14-
hcfmusp.scopus.lastupdate2024-04-12-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC


Files in This Item:
File Description SizeFormat 
art_SOUZA_Different_morphology_stage_and_treatment_affect_immune_cell_2012.PDF
  Restricted Access
publishedVersion (English)1.18 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.